Oruka Therapeutics, Inc. $ORKA Shares Bought by Affinity Asset Advisors LLC

Key Points

• Affinity Asset Advisors LLC increased its stake in Oruka Therapeutics by 47.9%, owning approximately 1.46% of the company, worth around $5.6 million.
• A consensus rating of "Buy" has been established for Oruka Therapeutics, with various analysts projecting a price target around $40.38.
• Oruka Therapeutics has shown a significant decline, with its stock down 6.0%, currently priced at $14.51.

Affinity Asset Advisors LLC increased its stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 47.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 545,362 shares of the company's stock after buying an additional 176,664 shares during the quarter. Affinity Asset Advisors LLC owned about 1.46% of Oruka Therapeutics worth $5,595,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Jane Street Group LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $343,000. Millennium Management LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $588,000. Squarepoint Ops LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $236,000. JPMorgan Chase & Co. acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $54,000. Finally, Barclays PLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $1,446,000. Institutional investors and hedge funds own 56.44% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ORKA shares. HC Wainwright reiterated a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research note on Monday, August 18th. Wall Street Zen lowered Oruka Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. BTIG Research began coverage on Oruka Therapeutics in a research note on Thursday, May 22nd. They set a "buy" rating for the company. Finally, Wedbush restated an "outperform" rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $40.38.

Oruka Therapeutics Stock Up 0.6%

Shares of ORKA traded up $0.09 during mid-day trading on Thursday, hitting $15.27. The stock had a trading volume of 109,577 shares, compared to its average volume of 148,808. The company has a market cap of $571.86 million, a PE ratio of -5.43 and a beta of -0.35. The company's fifty day simple moving average is $13.79 and its two-hundred day simple moving average is $11.66. Oruka Therapeutics, Inc. has a fifty-two week low of $5.49 and a fifty-two week high of $33.00.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.02. Equities analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.